Markets
← Back to Stocks
BMY
BRISTOL MYERS SQUIBB CO
Health Care · Pharmaceuticals
$58.17
-2.02%
Vol: 0.2M
Araverus Market Read
Thursday, March 19, 2026
Positive Phase 3 results and FDA approvals power Bristol-Myers pipeline strength weigh on modest gains
Bristol-Myers Squibb reported positive Phase 3 SUCCESSOR-2 results (March 8) and FDA approval of Sotyktu for psoriatic arthritis (March 6), with UBS raising price target to $70 from $65. Pre-market shows $59.24 down 0.49% and after-hours $59.05 down 0.05% reflecting limited overnight momentum despite positive pipeline catalysts. The pharmaceutical advances support long-term investor confidence.
Price 50d 200d
Previous Market Reads
2 of 2 daysSector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$118.3B
P/E (TTM)16.8
Forward P/E9.5
Beta0.27
Div Yield424.00%
Prev Close$59.37
RSI (14-Day)
25Oversold
0305070100
52-Week Range
$42.52$58.17$62.89
From High-7.5%
From Low+36.8%
Moving Averages
50d SMA
$58.52-0.6%
200d SMA
$49.59+17.3%
Price between 50d and 200d. Testing 50d support.
Returns
1W
-1.3%
1M
-2.6%
3M
+8.5%
6M
+29.3%
1Y
+2.0%
YTD
+8.8%
Volume
Today219K
20d Avg12.2M
Ratio0.02x